Advances in corticosteroid therapy for ocular inflammation: Loteprednol etabonate

International Journal of Inflammation

Volumn 2012, Issue , 2012, Pages

  Comstock, Timothy L ^a   Decory, Heleen H ^a  

^a BAUSCH AND LOMB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; FLUOROMETHOLONE; GLUCOCORTICOID RECEPTOR; LENS PROTEIN; LOTEPREDNOL ETABONATE; OLOPATADINE; PLACEBO; PREDNISOLONE; PREDNISOLONE ACETATE; TOBRAMYCIN;

ALLERGIC CONJUNCTIVITIS; ANTERIOR EYE SEGMENT; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; CATARACTOGENESIS; CONJUNCTIVAL HYPEREMIA; CORTICOSTEROID THERAPY; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EYE INFLAMMATION; EYE PAIN; GIANT PAPILLARY CONJUNCTIVITIS; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; IRIDOCYCLITIS; KERATITIS; KERATOCONJUNCTIVITIS; KERATOCONJUNCTIVITIS SICCA; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); NONHUMAN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEASONAL ALLERGIC CONJUNCTIVITIS; SIDE EFFECT; STRUCTURE ANALYSIS;

EID: 84872779513     PISSN: 20908040     EISSN: 20420099     Source Type: Journal    
DOI: 10.1155/2012/789623     Document Type: Review

References (52)

1. Stein-Streilein J., Streilein J. W., Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy. International Reviews of Immunology 2002 21 2-3 123 152 2-s2.0-0035997383 10.1080/08830180212066 (Pubitemid 34791937)
2. Lapalus P., Moulin G., Bayer V., Effects of a new anti-allergic agent: the magnesium salt of N-acetyl-aspartyl-glutamic acid on experimental allergic inflammation of the rabbit eye. Current Eye Research 1986 5 7 517 522 2-s2.0-0022493516 (Pubitemid 16007762)
3. Ferguson V. M. G., Spalton D. J., Recovery of the blood-aqueous barrier after cataract surgery. British Journal of Ophthalmology 1991 75 2 106 110 2-s2.0-0026017105
4. Abelson M. B., Schaefer K., Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Survey of Ophthalmology 1993 38 115 132 2-s2.0-0027317160 10.1016/0039-6257(93)90036-7 (Pubitemid 23239418)
5. Chambless S. L., Trocme S., Developments in ocular allergy. Current Opinion in Allergy and Clinical Immunology 2004 4 5 431 434 2-s2.0-4644291294 10.1097/00130832-200410000-00016 (Pubitemid 39274086)
6. Novack G. D., A double-masked, placebo-controlled evaluation of 0.5 loteprednol etabonate in the treatment of postoperative inflammation. Ophthalmology 1998 105 9 1780 1786 2-s2.0-0343640813 (Pubitemid 28513536)
7. Rhen T., Cidlowski J. A., Antiinflammatory action of glucocorticoidsnew mechanisms for old drugs. New England Journal of Medicine 2005 353 16 1711 1658 2-s2.0-26844433194 10.1056/NEJMra050541 (Pubitemid 41464710)
8. Newton R., Molecular mechanisms of glucocorticoid action: what is important? Thorax 2000 55 7 603 613 2-s2.0-0034130914 10.1136/thorax.55.7.603 (Pubitemid 30398277)
9. Stahn C., Buttgereit F., Genomic and nongenomic effects of glucocorticoids. Nature Clinical Practice Rheumatology 2008 4 10 525 533 2-s2.0-53849129191 10.1038/ncprheum0898
10. Stahn C., Löwenberg M., Hommes D. W., Buttgereit F., Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Molecular and Cellular Endocrinology 2007 275 1-2 71 78 2-s2.0-34547863538 10.1016/j.mce.2007.05.019 (Pubitemid 47259281)
11. Cidlowski J. A., Glucocorticoids and their actions in cells. Retina 2009 29 6 S21 S23 2-s2.0-68049137648 10.1097/IAE.0b013e3181ad2636
12. Schäcke H., Döcke W.-D., Asadullah K., khusru. asadullah@schering.de Mechanisms involved in the side effects of glucocorticoids. Pharmacology and Therapeutics 2002 96 1 23 43 10.1016/S0163-7258(02)00297-8 (Pubitemid 35346616)
13. McGhee C. N. J., Dean S., Danesh-Meyer H., Locally administered ocular corticosteroids benefits and risks. Drug Safety 2002 25 1 33 55 2-s2.0-0036192290 (Pubitemid 34208330)
14. Kersey J. P., Broadway D. C., Corticosteroid-induced glaucoma: a review of the literature. Eye 2006 20 4 407 416 2-s2.0-33645760204 10.1038/sj.eye. 6701895
15. Clark A. F., Wordinger R. J., The role of steroids in outflow resistance. Experimental Eye Research 2009 88 4 752 759 2-s2.0-64249159576 10.1016/j.exer.2008.10.004
16. Lütjen-Drecoll E., May C. A., Polansky J. R., Johnson D. H., Bloemendal H., Nguyen T. D., Localization of the stress proteins α B-crystallin and trabecular meshwork inducible glucocorticoid response protein in normal and glaucomatous trabecular meshwork. Investigative Ophthalmology and Visual Science 1998 39 3 517 525 (Pubitemid 28110683)
17. Manabe S., Bucala R., Cerami A., Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. Journal of Clinical Investigation 1984 74 5 1803 1810 2-s2.0-0021690560 (Pubitemid 15214094)
18. Bodor N., Shek E., Higuchi T., Improved delivery through biological membranes. 1. Synthesis and properties of 1-methyl-1,6-dihydropyridine-2- carbaldoxime, a pro-drug of N-methylpyridinium-2-carbaldoxime chloride. Journal of Medicinal Chemistry 1976 19 1 102 107 2-s2.0-0016907546
19. Bodor N., Buchwald P., Soft drug design: general principles and recent applications. Medicinal Research Reviews 2000 20 1 58 101 2-s2.0-0033966357 10.1002/(SICI)1098-1128(200001)20:158::AID-MED3>3.0.CO;2-X (Pubitemid 30027561)
20. Bodor N., Loftsson T., Wu W., Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Pharmaceutical Research 1992 9 10 1275 1278 2-s2.0-0026788230 10.1023/A:1015849132396
21. Alberth M., Wu W. M., Winwood D., Bodor N., Lipophilicity, solubility and permeability of loteprednol etabonate: a novel, soft anti-inflammatory steroid. Journal of Biopharmaceutical Sciences 1991 2 115 125
22. Druzgala P., Hochhaus G., Bodor N., Soft drugs10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. Journal of Steroid Biochemistry and Molecular Biology 1991 38 2 149 154 2-s2.0-0026100181
23. Druzgala P., Wu W. M., Bodor N., Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Current Eye Research 1991 10 10 933 937 2-s2.0-0025991941
24. Hochhaus G., Chen L. S., Ratka A., Druzgala P., Howes J., Bodor N., Derendorf H., Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. Journal of Pharmaceutical Sciences 1992 81 12 1210 1215 2-s2.0-0027053957 10.1002/jps.2600811217 (Pubitemid 23018130)
25. Bodor N., Wu W. M., Mrakami T., Engel S., Soft drugs 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats. Pharmaceutical Research 1995 12 6 875 879 2-s2.0-0028998734
26. Bodor N., Bodor N., Wu W. M., A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits. Current Eye Research 1992 11 6 525 530 2-s2.0-0026638362
27. ®) in rabbits with corneal inflammation. Proceedings of the Association for Research in Vision and Ophthalmology Meeting 2010 Ft. Lauderdale, Fla, USA
28. Samudre S. S., Lattanzio F. A., Williams P. B., Sheppard J. D., Comparison of topical steroids for acute anterior uveitis. Journal of Ocular Pharmacology and Therapeutics 2004 20 6 533 547 2-s2.0-10344253285 10.1089/jop.2004.20.533 (Pubitemid 39628498)
29. Bartlett J. D., Howes J. F., Ghormley N. R., Amos J. F., Laibovitz R., Horwitz B., Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Current Eye Research 1993 12 4 313 321 2-s2.0-0027311235 (Pubitemid 23162150)
30. Asbell P., Howes J., A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO Journal 1997 23 1 31 36 2-s2.0-0031021022 (Pubitemid 27043763)
31. Friedlaender M. H., Howes J., A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. American Journal of Ophthalmology 1997 123 4 455 464 (Pubitemid 27171850)
32. Dell S. J., Shulman D. G., Lowry G. M., Howes J., A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. American Journal of Ophthalmology 1997 123 6 791 797 (Pubitemid 27250926)
33. Dell S. J., Lowry G. M., Northcutt J. A., Howes J., Novack G. D., Hart K., A randomized, double-masked, placebo-controlled parallel study of 0.2 loteprednol etabonate in patients with seasonal allergic conjunctivitis. Journal of Allergy and Clinical Immunology 1998 102 2 251 255 2-s2.0-0031722635
34. Shulman D. G., Lothringer L. L., Rubin J. M., Briggs R. B., Howes J., Novack G. D., Hart K., A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2 in patients with seasonal allergic conjunctivitis. Ophthalmology 1999 106 2 362 369 2-s2.0-0033511435 (Pubitemid 30191638)
35. Elion-Mboussa A., Gong L., Roy L., Zhu B., DeCory H., Chu E., Loteprednol etabonate ophthalmic suspension, 0.2 is as safe as olopatadine hydrochloride ophthalmic solution, 0.1 with superior relief of signs and symptoms in the treatment of seasonal allergic conjunctivitis. Proceedings of the Annual Meeting of the American Academy of Allergy Asthma and Immunology March 2012 Orlando, Fla, USA
36. Cohen C. R., Davis J., DeBarge R., Foley J., Foster C. S., Fox K., Friedlaender M., John G., Kaufman A., Nozik R., Olander K., Ostrov C., Raizman M., Rosenbaum J., Sall K., Sheppard J., Stewart D., Tauber J., Trocme S., Zimmerman P., Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. American Journal of Ophthalmology 1999 127 5 537 544 10.1016/S0002-9394(99)00034-3 (Pubitemid 29215764)
37. Cheng J. W., Wei R. L., Li Y., Safety and efficacy of loteprednol for ocular inflammation: a meta-analysis. Chinese Journal of New Drugs and Clinical Remedies 2003 22 5 259 263
38. Pflugfelder S. C., Maskin S. L., Anderson B., Chodosh J., Holland E. J., De Paiva C. S., Bartels S. P., Micuda T., Proskin H. M., Vogel R., A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5 and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. American Journal of Ophthalmology 2004 138 3 444 457 2-s2.0-4444368235 10.1016/j.ajo.2004.04.052 (Pubitemid 39208573)
39. Sheppard J. D., Scoper S. V., Samudre S., Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease. Journal of Ocular Pharmacology and Therapeutics 2011 27 1 23 27
40. Donnenfeld E., Sheppard J. D., Holland E. J., Prospective, multicenter, randomized controlled study on the effect of loteprednol etabonate on initiating therapy with cyclosporine A. Proceedings of the American Academy of Ophthalmology Annual Meeting November 2007 New Orleans, La, USA
41. Stewart R., Horwitz B., Howes J., Novack G. D., Hart K., Alpar J., Bokosky J., Coheen G. R., Donshik P., Helms H., Horwitz B., Lehman R., Macsai M., Olson R., Pickett J., Raizmann M., Stamler J., Stewart R., Syverud J., Tauber J., Trocme S., Wong M., Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5 for postoperative inflammation. Journal of Cataract and Refractive Surgery 1998 24 11 1480 1489 (Pubitemid 28509816)
42. Comstock T. L., Usner D. W., Effect of loteprednol etabonate ophthalmic suspension 0.5 on post-operative pain and discomfort. Proceedings of the American Society of Cataract and Refractive Surgery Meeting 2010
43. White E. M., Macy J. I., Bateman K. M., Comstock T. L., Comparison of the safety and efficacy of loteprednol 0.5/tobramycin 0.3 with dexamethasone 0.1/tobramycin 0.3 in the treatment of blepharokeratoconjunctivitis. Current Medical Research and Opinion 2008 24 1 287 296 2-s2.0-38749147307 10.1185/030079908X253898 (Pubitemid 351181204)
44. Chen M., Gong L., Sun X., Comparison of the safety and efficacy of loteprednol etabonate 0.5 tobramycin 0.3 5 with dexamethasone 0.1/tobramycin 0.3 in the treatment of Chinese patients with blepharokeratoconjunctivitis. Current Medical Research Opinion. In press
45. Comstock T. L., tcomstock@bausch.com Paterno M. R., Singh A., Erb T., Davis E., Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5 for the treatment of inflammation and pain following cataract surgery. Clinical Ophthalmology 2011 5 1 177 186 10.2147/OPTH.S16832
46. Holland E. J., Bartlett J. D., Paterno M. R., Usner D. W., Comstock T. L., Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea 2008 27 1 50 55 2-s2.0-40449102558
47. Bartlett J. D., Holland E. J., Usner D. W., Paterno M. R., Comstock T. L., Tolerability of loteprednol/tobramycin versus dexamethasone/tobramycin in healthy volunteers: results of a 4-week, randomized, double-masked, parallel-group study. Current Medical Research and Opinion 2008 24 8 2219 2227 2-s2.0-50149102171 10.1185/03007990802231981
48. Novack G. D., Howes J., Crockett R. S., Sherwood M. B., Change in intraocular pressure during long-term use of loteprednol etabonate. Journal of Glaucoma 1998 7 4 266 269 2-s2.0-0032467764 (Pubitemid 29149820)
49. Ilyas H., Slonim C. B., Braswell G. R., Favetta J. R., Schulman M., Long-term safety of loteprednol etabonate 0.2 in the treatment of seasonal and perennial allergic conjunctivitis. Eye and Contact Lens 2004 30 1 10 13 2-s2.0-1842433686 10.1097/01.ICL.0000092071.82938.46 (Pubitemid 43196972)
50. Bartlett J. D., Horwitz B., Laibovitz R., Howes J. F., Intraocular pressure response to loteprednol etabonate in known steroid responders. Journal of Ocular Pharmacology 1993 9 2 157 165 2-s2.0-0027159211 (Pubitemid 23187584)
51. Holland E. J., Djalilian A. R., Sanderson J. P., Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5 in steroid responders after corneal transplantation. Cornea 2009 28 10 1139 1143 2-s2.0-77449144002
52. Bodor N., bodor@cop.ufl.edu Buchwald P., Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS Journal 2005 7 4, article 79 10.1208/aapsj070479 (Pubitemid 41819441)